Navigation Links
Lilly Improves Its Environmental Footprint in Business Operations and Helps Beautify Communities
Date:10/4/2011

INDIANAPOLIS, Oct. 4, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that it is improving its environmental footprint by achieving two of the company's three environmental goals ahead of schedule. Through the end of 2010, the company reduced the amount of waste sent to landfills by about 50 percent and has reduced its water intake by more than 30 percent. Lilly remains on track to meet its energy goal. Lilly has improved the energy efficiency of its operations by almost 12 percent while greenhouse gas emissions have been reduced by more than 9 percent through 2010.  

The goals were established for a five-year period beginning in 2008, using 2007 performance as a baseline. The company had aimed for a 40 percent reduction in waste to landfills and a 25 percent reduction in water intake by 2013. By 2013, the company hopes to achieve a 15 percent improvement in energy efficiency and in reducing greenhouse gas emissions.

"Through the efforts of our employees worldwide, we're making great progress to lessen our environmental impact in the communities where we operate," said Steve Gillman, vice president of health, safety, and environment. "We take this responsibility seriously and remain committed to finding more ways to use resources more efficiently and improve our performance."

Lilly has been able to avoid disposing of waste by reducing, reusing, and recycling in its business operations. Such efforts have resulted in only 10 percent of waste being sent to landfills last year. The company has six locations that have achieved a zero-landfill status including facilities in research, manufacturing and distribution.

Overall in 2010, the company reused approximately 65 percent of its waste. For example, mycelia, a solid material left after a fermentation process, is being used as a soil conditioner on farmland to improve plant
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... , Nov. 20, 2014   Wellcentive , ... (PHM) for healthcare organizations, announced today being named ... 2014 Intel Innovation Award .  Sponsored by Intel, ... in its fourth year, recognizes companies developing leading-edge ... healthcare delivery processes. Wellcentive,s ...
(Date:11/21/2014)... Nov. 21, 2014  Lexicon Pharmaceuticals, Inc. (Nasdaq: ... its offering of $80,000,000 aggregate principal amount of 5.25% ... a private offering within the United States ... institutional buyers pursuant to Rule 144A under the Securities ... has also granted the initial purchasers an option to ...
(Date:11/18/2014)... WALTHAM, Mass. , Nov. 18, 2014 ... one of the leading medical device and services providers ... Motion,s exclusive partner for Respiratory Motion,s innovative respiratory depression ... Respiratory Motion and IMI are working together to connect ... IMI has a long history of bringing innovative medical ...
Breaking Medicine Technology:Wellcentive Named Finalist for 2014 Intel Innovation Award 2Wellcentive Named Finalist for 2014 Intel Innovation Award 3Lexicon Announces Pricing Of Convertible Senior Notes Offering 2Lexicon Announces Pricing Of Convertible Senior Notes Offering 3Prominent Japanese Med Device Provider to be Respiratory Motion's Exclusive Partner for World's #2 Medical Market 2Prominent Japanese Med Device Provider to be Respiratory Motion's Exclusive Partner for World's #2 Medical Market 3Prominent Japanese Med Device Provider to be Respiratory Motion's Exclusive Partner for World's #2 Medical Market 4
... Pharmaceuticals Inc . (Nasdaq: CPIX) is pleased to ... Directors. A healthcare veteran with more than 30 ... President and Chief Executive Officer of Nashville-based Psychiatric Solutions, Inc. ... $2 billion behavioral healthcare system before the company,s sale to ...
... Jan. 6, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: ... China, announced today its preliminary unaudited sales range for the ... conference call to discuss these preliminary sales will be held ... (January 6, 2011 at 9:00 pm China Standard Time). The ...
Cached Medicine Technology:Cumberland Pharmaceuticals Announces Joey Jacobs Has Joined Its Board of Directors 2Sinovac Provides Preliminary Unaudited Fourth Quarter 2010 Sales Range 2Sinovac Provides Preliminary Unaudited Fourth Quarter 2010 Sales Range 3
(Date:11/21/2014)... Florida (PRWEB) November 21, 2014 Nature’s Sleep is ... Sleep contest . The contest calls for the creation of any ... a photo — that encompasses sleep, a bed or a mattress. ... year,” said Alan Hirschhorn, Vice President of Marketing for Nature’s Sleep, ... an array of more than 10,000 creative entries from some very ...
(Date:11/21/2014)... HealthDay Reporter THURSDAY, Nov. 20, 2014 ... of a still-beating heart has the potential to improve the ... new study. Heart patients who received the gel implant ... hundreds of feet farther during a six-minute walk test, said ... cardiovascular division at Washington University School of Medicine and a ...
(Date:11/21/2014)... HealthDay Reporter THURSDAY, Nov. ... excess or binge drink are not alcoholics, a new U.S. ... who drink too much aren,t dependent on alcohol. But one ... Centers for Disease Control and Prevention. , , "A lot of ... alcoholics," said study co-author Dr. Robert Brewer, the leader of ...
(Date:11/18/2014)... November 18, 2014 Cristcot Inc., ... development and commercialization of specialized drug delivery systems, ... granted Cristcot a patent for the technology, which ... Sephure®. , The patent was awarded to ... rights have been assigned to Cristcot Inc. The ...
(Date:11/18/2014)... HealthDay Reporter MONDAY, ... cholesterol down to extremely low levels with a combination ... in high-risk patients with clogged arteries, a new study ... when taking Vytorin, a drug that combines a cholesterol-lowering ... said principal investigator Dr. Christopher Cannon, a cardiologist at ...
Breaking Medicine News(10 mins):Health News:Nature’s Sleep Kicks Off their 2nd Art Of Sleep Contest 2Health News:Gel Implant Might Help Fight Heart Failure 2Health News:Gel Implant Might Help Fight Heart Failure 3Health News:Many People Who Drink a Lot Aren't Alcoholics: CDC 2Health News:Many People Who Drink a Lot Aren't Alcoholics: CDC 3Health News:Japanese Patent Office Grants Patent to Cristcot Inc. 2Health News:Cholesterol Drug Vytorin Linked to Reduced Heart Attack Risk 2Health News:Cholesterol Drug Vytorin Linked to Reduced Heart Attack Risk 3
... HARRISBURG, Pa. , Sept. 8 ... for subsidized health insurance coverage, state Insurance Commissioner Joel Ario today urged ... that will give Pennsylvania and other states tools needed to fix the ... , "Lost in the din of the recent town hall ...
... Delta Health , an InfoLogix, ... that it has been selected by Hennepin County Medical Center in ... impact margins through productivity management. , , (Logo: ... , Delta Health has helped hospitals across North America ...
... , NEW YORK, Sept. 8 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) ... that it has filed a patent for a novel ... thus has blockbuster potential as a new anti-cancer drug. ... which is highly reactive to prostate cancer cells, and ...
... Sept. 8 MRSA Survivors Network, the Chicago-based nonprofit and official ... lift the veil of secrecy surrounding MRSA. The history making ... October 1st. The 2009 theme is "You Can Not Change What ... http://www.newscom.com/cgi-bin/prnh/20090825/DC65136LOGO ) , , Founder ...
... , NEW YORK, Sept. 8 NeoStem, ... pioneering the pre-disease collection, processing and long-term storage of adult stem ... Robin Smith, M.D., MBA, will present on the Company,s latest strategic ... New York Palace Hotel in New York City on September 9-11, ...
... , , WALTHAM, Mass., ... the global authority on medical technology market intelligence, the ... experience considerable growth in sales over the next five ... 2009 report finds, however, that product safety issues ...
Cached Medicine News:Health News:Insurance Commissioner Says Federal Health Care Reform Necessary to Fix a Broken System 2Health News:Delta Health, an InfoLogix Company, Wins Engagement with Hennepin County Medical Center for Strategic Cost Management 2Health News:Delta Health, an InfoLogix Company, Wins Engagement with Hennepin County Medical Center for Strategic Cost Management 3Health News:Genova files patent for new prostate cancer treatment 2Health News:MRSA Activists to Lift the Veil of Secrecy on World MRSA Day 2Health News:NeoStem to Present at Rodman & Renshaw's 11th Annual Healthcare Conference 2Health News:NeoStem to Present at Rodman & Renshaw's 11th Annual Healthcare Conference 3Health News:Will the FDA Ban Hydroquinone in Pigment Control Products? 2Health News:Will the FDA Ban Hydroquinone in Pigment Control Products? 3
Using proven 1064 nm technology for the treatment of deeper lesions, the Lumenis One Multi-Spot Nd:YAG module provides versatility allowing targeted treatment of leg veins, vascular lesions, facial w...
... people are diagnosed with varicose veins every ... never seek treament and are apprehensive of ... them an effective alternative to conventional therapies., ... hook phlebectomy), is considered a laborious procedure ...
Inquire...
...
Medicine Products: